S-adenosylmethionine (SAMe): early-stage discoveries

In the lab, doctors introduced S-adenosylmethionine (SAMe) into human breast cancer cells and found a direct link between the dosage of SAMe and decreases in cell proliferation, invasion, migration, growth, and programmed cell death.

SAMe also reduced tumor size and the spread from an initial cancer site to other sites. Doctors analyzed gene expression and found SAMe decreased the expression of several key genes that promote cancer growth and spread. Discussing the findings, doctors said the results provide compelling evidence that SAMe can reduce cancer-related disability and death, and call for further therapeutic study.


Next Back to Top
More Related Articles